PubMed Trending Research Digest — September 01, 2026

Automated digest · 96 articles · 15 research areas · September 01, 2026

Overview

The week’s cardiovascular research is dominated by a “precision prevention” theme: large-scale observational and pooled trial analyses refine who benefits from interventions (e.g., vaccination’s longer-term cardiovascular effects after COVID-19, blood-pressure time-in-range for HFpEF/HFmrEF, and Lp(a) risk across age/sex). Several studies also focus on optimizing antithrombotic strategies—balancing bleeding and ischemic risk in AF after PCI, and tailoring post–TAVR regimens to reduce imaging-defined thrombosis—reflecting a shift from one-size-fits-all regimens toward risk- and context-aware choices.

Across oncology and immunology, mechanistic work continues to connect molecular switches to disease behavior. Multiple papers highlight epitranscriptomic and stress-response control (m6A readers like YTHDC1/YTHDF2, lactylation-driven metabolic rewiring, and ubiquitin/deubiquitinase regulation) as drivers of cancer progression, resistance, and cell-death pathways (pyroptosis, ferroptosis, cuproptosis resistance). In parallel, immune and inflammatory signaling is repeatedly implicated as a causal bridge to tissue injury—such as cytokine–ROS–Ca2+ signaling in severe inflammatory cardiomyopathy and immune-activated co-culture models aimed at more faithful treatment sequencing.

Neurology and biomarker development show strong translational momentum. Studies validate plasma biomarkers (p-tau217) for amyloid status and progression prediction in Alzheimer’s disease, while other work maps neurocircuit mechanisms for pain/itch and goal-directed action. Together with advances in single-cell and spatial technologies (including mitochondrial phenotype-coupled mtDNA sequencing), the overall picture is of increasingly quantitative, mechanism-linked approaches—aiming to turn complex biology into actionable diagnostics and targeted therapies.

---

Cardiovascular Prevention & Risk Stratification

Single-cell profiling of mitochondrial phenotyping-coupled mtDNA genotyping.

The study developed and applied human single-cell mitochondrial phenotype-coupled mtDNA sequencing (scMPCDS) to simultaneously measure mtDNA heteroplasmy/mutations and mitochondrial functional phenotypes (membrane potential and reactive oxygen species) in individual cells. Using scMPCDS, the authors showed that DdCBE-mediated mtDNA editing/genomic instability can be directly linked to mitochondrial functional outcomes at single-cell resolution. This integrated single-cell genotype–phenotype platform enables mechanistic mapping of mitochondrial DNA instability to bioenergetic and oxidative stress phenotypes, which could accelerate mitochondrial disease research and therapeutic evaluation.

Zhang Z, Zhang L, An P et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.

This study used multivariable-adjusted plasma proteomic profiling across 2918 proteins in a UK Biobank primary prevention cohort (n=35,269) to derive proteomic signatures associated with apolipoprotein B-containing lipoprotein subclasses (LDL, triglyceride-rich lipoproteins, and lipoprotein(a)). The key finding was that distinct proteomic signatures for LDL, TRL, and Lp(a) reflect different biological processes and per-particle atherogenicity, supporting subclass-specific mechanisms in coronary artery disease. These results provide proteomic biomarkers and mechanistic targets to refine risk stratification and therapeutic strategies for different apolipoprotein B lipoprotein drivers.

Morze J, Björnson E, Mi MY et al. · European heart journal · (2026) · View on PubMed ↗

Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.

This international randomized noninferiority trial studied the optimal sequencing of coronary revascularization in patients with severe aortic stenosis and coronary artery disease undergoing transcatheter aortic-valve implantation (TAVI), comparing TAVI-first versus PCI-first strategies. The key finding was the comparative safety/noninferiority of one sequencing strategy over the other for a composite clinical endpoint including death and nonfatal myocardial infarction (with additional ischemic outcomes). Clinically, the trial informs guideline decisions on whether to perform PCI before or after TAVI to minimize adverse events in this common comorbidity setting.

Stähli BE, Ruschitzka F, Westermann D et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Pulmonary Denervation for Heart Failure-Related Pulmonary Hypertension.

This multicenter randomized trial evaluated pulmonary-artery denervation added to guideline-directed medical therapy versus guideline-directed medical therapy alone in patients with pulmonary hypertension due to left heart disease and heart failure in China. The key finding was the effect of pulmonary-artery denervation on clinical outcomes related to pulmonary hypertension in this population (as assessed in the trial’s randomized design). If beneficial, pulmonary denervation could become an adjunctive device-based therapy targeting sympathetic overactivation to improve outcomes in left-heart-disease-associated pulmonary hypertension.

Zhang H, Wang Q, Liang M et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Tricuspid-Valve Intervention in Heart Failure.

This randomized trial studied transcatheter tricuspid-valve repair plus medical therapy versus medical therapy alone in patients with symptomatic severe tricuspid regurgitation at increased risk for future heart-failure events. The key finding was the between-group difference in a hierarchical primary endpoint at 1 year combining death, hospitalization for heart failure, and quality-of-life improvement assessed using a win-ratio framework. The results clarify whether transcatheter tricuspid repair improves survival and morbidity beyond medical therapy in high-risk tricuspid regurgitation.

Hausleiter J, Stocker TJ, Geisler T et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.

This phase 3 randomized placebo-controlled trial evaluated milvexian, an oral factor XIa inhibitor, added to standard antiplatelet therapy within 7 days after an acute coronary syndrome event. The key finding was whether milvexian reduced major adverse cardiovascular events (cardiovascular death, myocardial infarction, or ischemic stroke) while maintaining minimal bleeding risk compared with placebo. If effective, factor XIa inhibition with milvexian could offer a new antithrombotic strategy to prevent recurrent ischemic events after ACS with potentially less bleeding.

Gibson CM, Steg PG, Bahit MC et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults.

This double-blind randomized placebo-controlled trial studied atorvastatin 40 mg daily versus placebo in community-dwelling adults aged at least 70 years without prior cardiovascular disease, diabetes, or dementia in Australia. The key finding was the effect of atorvastatin on cardiovascular outcomes and disability-free survival in older adults. The results address whether statin therapy provides meaningful benefit and functional preservation in late-life primary prevention.

Zoungas S, Wolfe R, Moran C et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI.

This multicenter open-label randomized trial studied aspirin omission at the time of primary PCI in patients with ST-segment elevation myocardial infarction (STEMI), comparing low-dose prasugrel monotherapy versus dual antiplatelet therapy with aspirin plus low-dose prasugrel for 12 months. The key finding was the noninferiority/safety of prasugrel monotherapy relative to DAPT for a composite outcome of death, stroke, or myocardial infarction at 12 months. Clinically, the trial informs whether aspirin can be safely omitted upfront in STEMI patients undergoing primary PCI to simplify therapy and potentially reduce bleeding risk.

Takahashi K, Kozuma K, Morino Y et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Prevalence of Silent Atherosclerosis across Adult Life.

This prospective cohort study quantified the prevalence and distribution of silent atherosclerosis across adult life by age and sex in Denmark and Spain, enrolling adults aged 18–70 years without known atherosclerotic cardiovascular disease. The key finding was the age- and sex-specific prevalence and vascular territory/plaque-volume patterns of subclinical atherosclerosis across the adult lifespan. These data improve understanding of when atherosclerosis begins and how it accumulates silently, supporting earlier prevention strategies.

Bundgaard H, García-Lunar I, Kofoed KF et al. · The New England journal of medicine · (2026) · View on PubMed ↗

Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial.

The VICTORION-Challenge phase 4 trial compared inclisiran versus bempedoic acid for LDL-C lowering in high-risk ASCVD patients already on statins (± ezetimibe). The key finding was the relative percentage change in LDL-C at Day 150 and related target attainment outcomes between the two direct/indirect LDL-lowering approaches. This head-to-head evidence helps clinicians choose among non-statin therapies to achieve LDL-C targets in patients with insufficient response to statins.

Hilgendorf I, Westermann D, Nowak B et al. · European heart journal · (2026) · View on PubMed ↗

The m⁶A reader YTHDF2 regulates mRNA transport and axon outgrowth in developing neurons.

This study examined how the m6A “reader” YTHDF2 regulates mRNA transport and axon outgrowth in developing neurons, focusing on m6A installed by the METTL3/METTL14 complex. YTHDF2 controlled the localization/transport of specific mRNAs required for proper axon extension during neuronal development. These findings link m6A post-transcriptional regulation to neuronal wiring and suggest YTHDF2 as a mechanistic node for neurodevelopmental dysfunction.

Koo B, Kumar A, Hwang H et al. · Nature communications · (2026) · View on PubMed ↗

The basolateral amygdala decodes visceral pain and itch via distinct circuits and molecules.

This study investigated how the basolateral amygdala (BLA) distinguishes visceral pain versus itch in mice, using function-labeled single-cell sequencing to identify molecularly defined neuronal populations. Two distinct BLA neuronal populations selectively encoded visceral pain and itch and projected to different downstream targets—the ventromedial hypothalamus (VMH) and dorsomedial striatum (DMS)—with Fgf2 and Notch2 implicated in these populations. The work clarifies circuit-level segregation of visceral aversive sensations and identifies candidate molecules for targeted modulation of pain/itch pathways.

Zhao Q, Li YC, Yao JH et al. · Nature communications · (2026) · View on PubMed ↗

Perinatal lead (Pb) exposure and alterations to amyloid beta and metabolic profiles in the brain.

This study assessed whether perinatal lead (Pb) exposure alters dementia-related brain outcomes in a murine model, measuring amyloid beta (Aβ) and using untargeted metabolomics in offspring at 3 weeks and 18 months. Perinatal Pb exposure produced significant changes in Aβ pathology (including diffuse Aβ and Aβ-positive cells) and altered metabolic profiles in plasma and cortex. These results support developmental Pb as a contributor to dementia risk through combined neuropathology and systemic/brain metabolic dysregulation.

Morgan RK, Matei EK, Pan J et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer’s disease progression.

This multi-cohort study evaluated the longitudinal diagnostic and prognostic performance of baseline plasma phosphorylated tau217 (p-tau217) for predicting amyloid-β PET (Aβ-PET) positivity and subsequent Alzheimer’s disease progression in 2117 individuals. Baseline-defined p-tau217 cutoffs showed high, sustained accuracy (86–95%) for Aβ-PET positivity over up to 5 years, with most p-tau217-positive individuals remaining stable (93–98%) while an intermediate group more often progressed to positivity. The findings validate plasma p-tau217 as a stable biomarker for tracking amyloid status and forecasting AD progression.

Lan G, Liao W, Jiang M et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗ · Free PDF ↗

Group A Streptococcus molecular point of care testing in a paediatric emergency department.

This pilot study tested a molecular point-of-care test (POCT) for Group A Streptococcus in a pediatric emergency department, enrolling children <16 years who also had a conventional throat swab for culture. The POCT was designed to assess whether it could alter management, and the research swab result did not affect clinical management while conventional culture was used for standard care. The study supports feasibility of molecular POCT workflows in pediatric ED settings and motivates larger trials to determine impact on antibiotic stewardship and outbreak prevention.

Mills EA, Bingham R, Nijman RG et al. · The Journal of antimicrobial chemotherapy · (2026) · View on PubMed ↗ · Free PDF ↗

DLST Succinylation-Mediated Mitochondrial Metabolic Remodeling and Cuproptosis Resistance Promote Malignant Progression of Lung Adenocarcinoma.

This study investigated how DLST (dihydrolipoamide S-succinyltransferase) succinylation at lysine 409 (K409) and cuproptosis resistance promote malignant progression in lung adenocarcinoma (LUAD), using succinylation proteomics and mechanistic perturbations. DLST K409 succinylation was increased in LUAD and was catalyzed by CPT1A, and this modification promoted tumor progression while enhancing resistance to cuproptosis. The work identifies a CPT1A–DLST succinylation axis as a potential therapeutic target to overcome cuproptosis-related treatment resistance in LUAD.

Li X, Zhou P, Peng X et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Space Jam-Ming: Generating Interstitial Space Using Fragmented Granular GelMA to Investigate Novel Paradigms of Cancer Metastasis.

This study developed “Space Jam-Ming,” a fragmented granular GelMA hydrogel platform to create interstitial space with controlled mechanical properties for modeling cancer metastasis. By decoupling stiffness from porosity relative to conventional 3D photo-crosslinkable hydrogels, the scaffold enabled investigation of how ECM-like mechanics regulate cellular plasticity relevant to metastasis, including epithelial-to-mesenchymal transition and adherent-to-suspension transition. The platform provides a tunable in vitro system to dissect biophysical drivers of metastatic behavior and to test anti-metastatic strategies under more realistic microenvironment conditions.

Vahala D, Lee ZM, Amos SE et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Extracellular matrix remodeling upregulates hippocampal neurogenic niche stiffness and impairs neurogenesis in Alzheimer’s disease.

This study examined whether extracellular matrix (ECM) remodeling increases hippocampal neurogenic niche stiffness and impairs neurogenesis in Alzheimer’s disease using 5×FAD mice and human AD samples. It measured SGZ stiffness with atomic force microscopy, profiled ECM components by proteomics, and used hydrogel supplementation to increase stiffness in wild-type mice and glycosaminoglycanase injections to reduce stiffness in 5×FAD mice, alongside gene-expression analyses in neurogenic lineages. The results indicate that ECM-driven stiffness elevation is a causal biophysical barrier to adult hippocampal neurogenesis in AD.

Sun W, Yang B, Zheng H et al. · Alzheimer’s & dementia : the journal of the Alzheimer’s Association · (2026) · View on PubMed ↗

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk.

This narrative review summarized recent advances in polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS), emphasizing endocrine and metabolic dysfunction and cardiovascular risk. It highlights that PMOS is a lifelong multisystem disorder with insulin resistance and compensatory hyperinsulinemia as central mechanisms linking reproductive, psychological/dermatologic, and cardiometabolic outcomes. The review supports updated clinical framing and risk-focused management strategies for women with PMOS.

Forslund M, Melin J, Joham AE et al. · Journal of internal medicine · (2026) · View on PubMed ↗ · Free PDF ↗

ANGII Initiated HSF2 Trans-Activating HIF-1α Through Induction of ER Stress to Promote Cardiac Hypertrophy.

This study tested whether angiotensin II (ANGII) promotes cardiac hypertrophy by inducing ER stress that enables HSF2 to trans-activate HIF-1α in cardiomyocytes, using both in vitro and in vivo models. ANGII increased HIF-1α expression via an HSF2-dependent transcriptional mechanism associated with ER stress, supported by RT-PCR, Western blotting, immunocytochemistry/immunohistochemistry, luciferase reporter assays, and chromatin immunoprecipitation (ChIP). The findings connect the ANGII–ER stress–HSF2–HIF-1α axis to hypertrophic remodeling and suggest potential molecular targets for anti-hypertrophy therapies.

Cao R, Meng Q, Li G et al. · Clinical and experimental pharmacology & physiology · (2026) · View on PubMed ↗ · Free PDF ↗

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation.

This study tested the natural product toosendanin (TSN) in skin melanoma models and investigated its molecular target. TSN inhibited melanoma proliferation and cell-cycle progression, induced apoptosis, and suppressed metastasis, and it was shown to target basonuclin 2 (BNC2) for degradation, thereby suppressing PIK3CA transcription. By linking TSN’s PI3K pathway suppression to BNC2 degradation, the work supports BNC2 as a potential therapeutic vulnerability in melanoma.

Dai H, Zhang XM, Zhang JC et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.

This multicenter GRACIE trial studied ivonescimab combined with FOLFOX as first-line therapy or with paclitaxel/irinotecan or FOLFIRI as second-line therapy in patients with advanced or metastatic gastric cancer or esophagogastric junction cancer, regardless of PD-L1/HER2/CLDN-18.2 actionable targets. The key finding reported in the abstract is the trial design and intent to determine efficacy and safety of ivonescimab plus chemotherapy in this setting, building on prior non-small cell lung cancer results. If successful, this would establish whether the anti-ivonescimab strategy can improve outcomes in gastric/EGJC beyond standard chemotherapy across biomarker-defined and unselected populations.

Raimbourg J, Botsen D, Pernot S et al. · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · (2026) · View on PubMed ↗ · Free PDF ↗

Waist circumference provides improved cardiometabolic discrimination compared with body mass index in psoriatic disease: discrimination and reclassification analyses.

This cross-sectional study evaluated whether waist circumference outperforms body mass index (BMI) for cardiometabolic risk discrimination and reclassification in 572 consecutive patients with psoriasis and/or psoriatic arthritis. The key finding is that waist circumference was assessed as the superior anthropometric marker compared with BMI using principal component analysis (PCA), ROC curves, and sex-specific Youden-derived thresholds for clustered cardiometabolic burden (≥2 abnormalities). Clinically, identifying the better marker could improve cardiometabolic risk stratification and targeting of prevention in psoriatic disease.

Queiro R, Pardo E, Loredo M et al. · Postgraduate medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Genetic and Molecular Basis of Cone Opsin Phototransduction.

This review studied the genetic and molecular basis of cone opsin phototransduction in vertebrate cone cells, focusing on molecular interactions and structural/conformational mechanisms that are less well characterized than rod rhodopsin. The key finding is that cone phototransduction has distinct, incompletely resolved structural and mechanistic features at the cone opsin level. Scientifically, clarifying these molecular steps could inform models of color vision and guide future experiments targeting cone-specific signaling defects.

Cao H, Puig-Puig N, Cruz A et al. · Biochemistry. Biokhimiia · (2026) · View on PubMed ↗

A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression.

This case report studied a 58-year-old man with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who developed histologically confirmed relapse after prior lisocabtagene maraleucel and then received epcoritamab after presumed pseudoprogression. The key finding was complete remission after epcoritamab despite the earlier relapse-like presentation and limited response to radiotherapy and chemotherapy. This is clinically significant because it suggests that pseudoprogression can occur with bispecific antibodies and that epcoritamab may still induce durable responses in heavily pretreated DLBCL.

Takahara A, Yagi Y, Kanemasa Y et al. · Journal of clinical and experimental hematopathology : JCEH · (2026) · View on PubMed ↗ · Free PDF ↗

Comparative Effects of Guanidinoacetic Acid and Creatine on Body Composition, Muscle Strength, and Protein Metabolism Biomarkers in Older Adults: A Randomized Exploratory Pilot Trial.

This randomized, double-blind exploratory pilot trial studied 25 apparently healthy older adults (≥65 years) comparing 8 weeks of guanidinoacetic acid (GAA) versus creatine supplementation on body composition, muscle strength, and protein metabolism biomarkers. The key finding is the comparative effect of GAA relative to creatine on these muscle and metabolic endpoints (with the study designed to detect differences in the absence of resistance exercise). If GAA shows benefits comparable to or distinct from creatine, it could offer an alternative or adjunct strategy to improve age-related muscle and protein metabolism.

Todorovic N, Nedeljkovic D, Korovljev D et al. · Journal of nutritional science and vitaminology · (2026) · View on PubMed ↗ · Free PDF ↗

[Thiotepa-busulfan-fludarabine conditioning in allogeneic hematopoietic stem cell transplantation for blast-phase myeloproliferative neoplasm].

This Japanese case report studied a 64-year-old man with blast-phase myeloproliferative neoplasm (BP-MPN) arising from essential thrombocythemia and secondary myelofibrosis who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) after cytoreduction with azacitidine plus venetoclax. The key finding was the use of a thiotepa–busulfan–fludarabine (TBF) conditioning regimen from an HLA allele-matched unrelated donor, following prior disease progression. Scientifically and clinically, it supports feasibility and potential anti-leukemic activity of TBF conditioning in BP-MPN, a setting where relapse risk remains high.

Abe S, Izumi S, Tsukamoto S et al. · [Rinsho ketsueki] The Japanese journal of clinical hematology · (2026) · View on PubMed ↗

[Aplastic anemia developed after treatment with durvalumab].

This case report studied a 76-year-old woman with stage IIIB squamous cell lung carcinoma who developed pancytopenia after starting durvalumab maintenance therapy. The key finding was bone marrow biopsy showing hypocellular marrow without dysplasia, fibrosis, or hemophagocytosis, consistent with aplastic anemia developing after durvalumab. Clinically, it highlights durvalumab as a potential trigger of immune-mediated marrow failure and underscores the need for prompt recognition and management of cytopenias during PD-L1 inhibitor therapy.

Maeshima K, Sakayori Y, Yokoyama H et al. · [Rinsho ketsueki] The Japanese journal of clinical hematology · (2026) · View on PubMed ↗

Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial.

This randomised, double-blind, multicentre trial studied whether catheter ablation for symptomatic atrial fibrillation improves atrial fibrillation–related quality of life compared with a sham procedure in adults (≥18 years) with symptomatic paroxysmal or persistent AF in Germany and Poland. Patients assigned to pulmonary vein isolation (PVI) ablation (2:1 vs sham) were tested against a sham catheter procedure, with the primary endpoint being the between-group difference in AF-related quality of life (full results truncated in the abstract). If PVI-SHAM-AF shows superiority, it would strengthen evidence for guideline-recommended catheter ablation as a symptom-relieving intervention beyond placebo effects in paroxysmal/persistent AF.

Wachter R, Haag P, Uhe T et al. · Lancet (London, England) · (2026) · 2 citations · View on PubMed ↗ · Free PDF ↗

Cardiovascular disease in pregnancy: physiology, global burden, risk stratification, and opportunities in care.

This Lancet Series examined cardiovascular disease in pregnancy across the continuum from preconception to lifelong surveillance, focusing on haemodynamic changes, congenital/acquired heart disease before pregnancy, and the performance of established risk-stratification tools in global settings. It highlights that pregnancy-related cardiovascular complications are often under-recognised and variably managed worldwide, and emphasizes multidisciplinary care and improved risk stratification. Clinically, the Series aims to reduce maternal mortality and long-term morbidity by improving identification and management of women at elevated cardiovascular risk around pregnancy.

Brazile TL, Conrad N, Bergman L et al. · Lancet (London, England) · (2026) · 1 citations · View on PubMed ↗

Adverse pregnancy outcomes and long-term cardiovascular disease risk.

This Lancet Series reviewed how adverse pregnancy outcomes (APOs)—including hypertensive disorders of pregnancy, gestational diabetes, and preterm birth (<37 weeks)—identify women with substantially higher long-term cardiovascular morbidity and mortality risk. It proposes that excess risk reflects both pre-existing cardiometabolic/genetic susceptibility and the haemodynamic/metabolic stressors of pregnancy that accelerate future disease. Scientifically and clinically, the synthesis supports using APO history for cardiovascular risk stratification and long-term surveillance after pregnancy.

Pabón MA, Smith G, Sharma G et al. · Lancet (London, England) · (2026) · 1 citations · View on PubMed ↗

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease Among Adults Aged 20 to 100 Years.

This study evaluated whether the association between high lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease (ASCVD) differs by age and sex in 103,341 adults (Copenhagen General Population Study) aged 20–100 years, including 18,322 participants aged 70–100 years. It estimated age-stratified incidence rates and hazard ratios for ASCVD for high Lp(a), with secondary analyses stratified further by sex (full effect estimates are truncated in the abstract). The findings are clinically significant because they could refine Lp(a)-based risk assessment and prevention strategies across the lifespan, especially in older adults.

Jeevanathan J, Thomas PE, Kamstrup PR et al. · Circulation · (2026) · View on PubMed ↗

Single-cell and spatial transcriptomic profiling identifies a fibroblast-like endothelial state and the MDK-NCL signaling axis in prostate cancer microenvironment remodeling.

This translational oncology study used single-cell RNA sequencing and spatial transcriptomics (integrated with bulk transcriptomic cohorts) to characterize endothelial heterogeneity in the prostate cancer microenvironment and identify a fibroblast-like endothelial (FLE) state. It reported an FLE population with mixed endothelial–stromal transcriptional features and an endothelial mesenchymal-like subset enriched for extracellular matrix remodeling and lipid metabolic programs, implicating an EndMT-like process and highlighting the MDK–NCL signaling axis (details truncated). Scientifically, defining the MDK–NCL axis and FLE/EndMT states could reveal actionable targets to modulate tumor microenvironment remodeling in prostate cancer.

Wang R, Li Y, Wang X · Translational oncology · (2026) · View on PubMed ↗ · Free PDF ↗

National survey of patients with neuromuscular disease and COVID-19 in Japan.

This retrospective questionnaire survey studied clinical features, transmission routes, treatments, and prognostic factors of COVID-19 in patients with neuromuscular disorders in Japan, using data from 13 neuromuscular disease centers for cases diagnosed between December 2019 and October 2022. It aimed to characterize severity and outcomes in this high-risk population and identify factors associated with prognosis (specific results are truncated in the abstract). The study is significant for guiding infection prevention, vaccination strategies, and clinical management of COVID-19 in neuromuscular patients.

Sato T, Ishigaki K, Kihara Y et al. · Brain & development · (2026) · View on PubMed ↗

Ligustilide and tectoridin from Danggui Buxue Decoction synergistically attenuate atherosclerosis by targeting the CD36/TRPM2 axis and TNF-α/NF-κB pathway.

This preclinical study investigated whether ligustilide and tectoridin—absorbed constituents from Danggui Buxue Decoction (DBD)—synergistically attenuate atherosclerosis by targeting the CD36/TRPM2 axis and the TNF-α/NF-κB pathway. It focused on multi-target mechanisms linking these pathways to atherosclerotic pathology (full experimental outcomes are truncated in the abstract). If supported by complete results, the work provides mechanistic rationale for DBD-derived compounds as potential anti-atherosclerotic therapeutics.

Li X, Zheng S, Song Y et al. · Phytomedicine : international journal of phytotherapy and phytopharmacology · (2026) · View on PubMed ↗ · Free PDF ↗

Associations of Illness Perception, Resignation Coping, and Social Support With Self-Regulatory Fatigue in Patients With Type 2 Diabetes: A Cross-Sectional Study.

This cross-sectional study examined associations among illness perception, resignation coping, social support, and self-regulatory fatigue (SRF) in 302 adults with type 2 diabetes mellitus recruited from a tertiary general hospital in China. It tested whether resignation coping and social support show indirect associations with SRF in the context of illness perception (specific statistical findings are truncated in the abstract). The results are clinically relevant because they could inform psychosocial interventions to reduce fatigue and improve self-management in T2DM.

Liu Q, Zhou Y, Li B et al. · Nursing open · (2026) · View on PubMed ↗ · Free PDF ↗

Brugada Syndrome in the Pediatric Population: Diagnostic Challenges and Clinical Outcome-Results of the German Multicenter Study COGIA.

This German multicenter retrospective study (COGIA) evaluated diagnostic challenges and clinical outcomes in 76 pediatric patients (children/adolescents) with suspected Brugada syndrome (BrS) across 12 tertiary care centers. It assessed applicability of current pediatric diagnostic criteria and tracked major arrhythmic events (MAE: sudden cardiac death, aborted cardiac arrest, and appropriate ICD therapy) and secondary outcomes including symptoms, pharmacotherapy, and device implantation (full outcome rates are truncated). The findings are significant for improving pediatric BrS diagnosis and risk stratification to guide treatment and device decisions in children.

Lippert L, Burkard T, Markel F et al. · Journal of cardiovascular electrophysiology · (2026) · View on PubMed ↗ · Free PDF ↗

Low-Voltage Ablation in Persistent Atrial Fibrillation: The IDEAL-AF Randomized Clinical Trial.

The IDEAL-AF randomized clinical trial studied whether adjunctive individualized low-voltage zone ablation improves outcomes beyond pulmonary vein isolation in patients with persistent atrial fibrillation at 5 Swedish ablation centers. The trial tested low-voltage substrate targeting identified by electroanatomical mapping versus pulmonary vein isolation alone, with 12-month follow-up to assess arrhythmia outcomes and health-related quality of life. If effective, this strategy would refine persistent AF ablation by using electroanatomical mapping to personalize lesion sets beyond standard pulmonary vein isolation.

Paul Nordin A, Charitakis E, Carnlöf C et al. · JAMA · (2026) · View on PubMed ↗

Cardiovascular Prevention among Healthcare Professionals: the ESC Congress Cardiovascular Health Check 2025.

The ESC Congress Cardiovascular Health Check 2025 evaluated cardiovascular risk profiles, awareness, treatment use, target achievement, and subclinical atherosclerosis (carotid ultrasonography) among healthcare professionals attending the ESC Congress (n=1366, with a subgroup). It compared HCPs without established ASCVD to age- and sex-matched characteristics and assessed how well preventive care targets were met and how frequently subclinical atherosclerosis was present. These findings are significant for designing occupational and system-level prevention programs to improve cardiovascular health among clinicians who deliver preventive care.

Wenzl FA, Wang Y, Mass V et al. · European heart journal · (2026) · View on PubMed ↗ · Free PDF ↗

Autophagic degradation of RAB8A promotes ferroptosis through dysregulation of TFRC-mediated iron uptake.

This study investigated how selective autophagy regulates ferroptosis by identifying RAB8A as an ATG5/ATG7-dependent autophagic substrate in cancer cells under ferroptotic stress. Ferroptotic stimuli induced RNF126-dependent polyubiquitination of RAB8A followed by SQSTM1-mediated autophagic degradation, and loss of RAB8A sensitized cells to ferroptosis while a degradation-resistant mutant (RAB8AQ67L) suppressed this effect. The work is significant because it links a specific autophagy–ubiquitin pathway (RNF126/SQSTM1) to iron uptake–driven ferroptotic sensitivity, suggesting potential targets to modulate ferroptosis in oncology.

Li J, Zhou Q, Liu J et al. · Autophagy · (2026) · View on PubMed ↗

Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies.

A post hoc analysis of two randomized phase 3 induction trials (U-EXCEL and U-EXCEED) and the 52-week maintenance trial (U-ENDURE) assessed the efficacy and safety of the oral JAK inhibitor upadacitinib in adults with moderate-to-severe Crohn’s disease in East Asia. The analysis evaluated outcomes after induction with upadacitinib 45 mg versus placebo and maintenance with upadacitinib 15 mg or 30 mg versus placebo among responders. Clinically, these results help determine whether upadacitinib’s benefit–risk profile in Crohn’s disease is consistent in East Asian populations and can inform region-specific treatment decisions.

Chen M, Gao X, Watanabe K et al. · Journal of gastroenterology · (2026) · View on PubMed ↗ · Free PDF ↗

Early SOX9 Activation Primes Hippo-YAP/TAZ Rewiring During Glioblastoma Stemness Acquisition.

This study used single-cell RNA sequencing, pseudotime reconstruction, spatial transcriptomics, and functional in vitro/in vivo assays to define how early SOX9 activation primes Hippo–YAP/TAZ rewiring during glioblastoma stemness acquisition. SOX9 expression peaked during the early astrocyte-to-malignant transition and then declined, showing inverse association with upstream Hippo kinase activity and phase-dependent coupling with YAP/TAZ-associated transcriptional programs. The findings are significant because they place SOX9 as a temporal regulator of Hippo–YAP/TAZ remodeling, identifying a potential early intervention point to disrupt glioblastoma stemness and plasticity.

Mijiti M, Li Y, Maimaiti A et al. · Journal of cellular and molecular medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Identifying Patients With Prostate Cancer Who Benefit Most From Routine Cardiovascular Specialist Referral.

This analysis studied the RADICAL PC-2 pragmatic randomized controlled trial population of patients with prostate cancer or receiving androgen-deprivation therapy to identify subgroups most likely to benefit from routine cardiovascular specialist referral. The intervention improved cholesterol control and overall outcomes, while rates of cardiovascular death, myocardial infarction, stroke, and heart failure were not different overall. The significance lies in enabling more targeted referral strategies for cardiovascular risk management in prostate cancer patients rather than one-size-fits-all care.

Cano Garcia C, Pinthus J, Avezum A et al. · JACC. CardioOncology · (2026) · View on PubMed ↗ · Free PDF ↗

Effect of In-Hospital Initiation of Dapagliflozin on Decongestion in Patients Hospitalized for Heart Failure: An Analysis of the DAPA ACT HF-TIMI 68 Trial.

This prespecified analysis of the randomized, placebo-controlled DAPA ACT HF-TIMI 68 trial evaluated whether in-hospital initiation of dapagliflozin affects multiple measures of congestion in patients hospitalized for heart failure. The study assessed placebo-adjusted changes from baseline in a modified EVEREST congestion framework over the early post-randomization period through 2 months. If dapagliflozin improves congestion metrics, it would support earlier initiation during hospitalization as a practical strategy to enhance decongestion and potentially improve downstream outcomes.

Small AM, Patel SM, Thomas C et al. · JACC. Heart failure · (2026) · View on PubMed ↗ · Free PDF ↗

Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: The NOTION-4 Trial.

The NOTION-4 randomized controlled trial studied antithrombotic strategies after transcatheter aortic valve replacement (TAVR) in patients without an indication for oral anticoagulation, comparing lifelong single antiplatelet therapy (SAPT) versus 3 months of DOAC followed by lifelong SAPT (DOAC-3m). The trial’s focus was prevention of subclinical leaflet thrombosis assessed by cardiac CT as hypoattenuated leaflet thickening (HALT). Clinically, the results are significant for optimizing post-TAVR antithrombotic regimens to reduce imaging-defined thrombosis while balancing bleeding and long-term management.

Jørgensen TH, Larsen AF, Jensen JM et al. · Journal of the American College of Cardiology · (2026) · View on PubMed ↗

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.

This study analyzed HELIOS-B to determine whether the treatment effect of vutrisiran (an RNA interference therapeutic suppressing hepatic transthyretin) differed according to baseline tafamidis use in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). It compared outcomes between vutrisiran and placebo within tafamidis users versus non-users to assess effect modification by concomitant transthyretin stabilization therapy. The significance is that it informs whether combining or sequencing vutrisiran with tafamidis could be clinically advantageous or unnecessary based on baseline use.

Hamatani Y, Claggett BL, Cuddy SAM et al. · Journal of the American College of Cardiology · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis.

This analysis of the HELIOS-B trial (654 randomized patients) evaluated whether concomitant disease-modifying therapy and other heart failure medications modified the efficacy of vutrisiran in ATTR cardiac amyloidosis. It characterized baseline and post-randomization initiation patterns by treatment arm and tested for treatment-effect modification by concurrent therapies. The findings are significant because they help determine how robust vutrisiran’s benefit is across real-world background regimens and guide combination therapy decisions.

Abovich A, Fontana M, Claggett B et al. · Journal of the American College of Cardiology · (2026) · 1 citations · View on PubMed ↗ · Free PDF ↗

COVID-19 Vaccination and Risk of Post-COVID-19 Cardiovascular Disease: A Population-Based Cohort and Target Trial Emulation Study.

This population-based cohort study and target trial emulation evaluated whether COVID-19 vaccination, including timing relative to SARS-CoV-2 infection, is associated with reduced long-term post-COVID cardiovascular disease risk in 2,391,456 adults in Victoria, Australia (2019–2025). Vaccination strategies were associated with lower risk of major adverse cardiovascular events (MACE) after infection, and the analysis quantified how much of the association could be explained by infection prevention. The results have public-health and clinical implications by linking vaccination to longer-term cardiovascular risk reduction beyond acute infection outcomes.

Seboka BT, Magliano DJ, Marwick TH et al. · European heart journal. Quality of care & clinical outcomes · (2026) · View on PubMed ↗ · Free PDF ↗

---

Atrial Fibrillation (AF) Management & Antithrombotics

Phenotypic clustering and ABC pathway adherence in patients with atrial fibrillation at high risk of bleeding and stroke: Insights from three global registries.

This study analyzed atrial fibrillation (AF) patients at high risk of both bleeding and stroke to identify clinical phenotypes and assess whether adherence to the ABC pathway predicts one-year outcomes. Using hierarchical clustering on patients with HAS-BLED ≥3 and CHA2DS2-VASc ≥2 across three global registries, it evaluated net adverse clinical events (NACE) in relation to ABC pathway adherence. The work aims to refine risk stratification and guide integrated AF care by linking phenotype and guideline adherence to clinical outcomes.

Askarinejad A, Bucci T, Tartaglia E et al. · European journal of internal medicine · (2026) · View on PubMed ↗ · Free PDF ↗

Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis.

This individual patient data network meta-analysis compared antithrombotic regimens after percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF), focusing on direct oral anticoagulants (DOAC) plus a P2Y12 inhibitor versus vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT). Using Cox proportional hazards models stratified by trial, the analysis estimated hazard ratios for bleeding and ischemic outcomes to address gaps in certainty and generalizability from prior randomized trials. The findings inform optimal post-PCI antithrombotic selection in AF by refining the balance between bleeding risk and ischemic protection.

Chiarito M, Mehran R, Gibson MC et al. · European heart journal · (2026) · View on PubMed ↗ · Free PDF ↗

---

Heart Failure (HF) Therapies & Biomarkers

Serial high-sensitivity troponin-T and risk of heart failure in individuals with suspected acute coronary syndrome.

This Danish registry study investigated how serial high-sensitivity cardiac troponin T (hs-TnT) patterns in individuals with suspected acute coronary syndrome (ACS) relate to subsequent heart failure risk. Participants were grouped by hs-TnT trajectory between first and second measurements (normal, rising, persistently elevated, falling) and by the magnitude of change and peak hs-TnT quartiles, and the study assessed the association with later heart failure. The clinical significance is that serial hs-TnT kinetics may improve risk prediction beyond a single troponin value in suspected ACS.

Erichsen PA, Afzal M, Byrne C et al. · International journal of cardiology · (2026) · View on PubMed ↗

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.

This pooled individual patient data analysis studied whether discontinuing β-blockers is non-inferior to continuing β-blockers in stable patients with prior myocardial infarction, preserved left ventricular ejection fraction (≥40%), and no heart failure, using data from the ABYSS and SMART-DECISION randomised trials. The key question was whether stopping β-blockers would be safe without worsening outcomes compared with continuation (specific results are truncated in the abstract). If non-inferiority is demonstrated, it would directly inform secondary prevention practice by potentially reducing unnecessary long-term β-blocker use in selected post-MI patients.

Silvain J, Choi KH, Monguillon V et al. · Lancet (London, England) · (2026) · 1 citations · View on PubMed ↗

SerpinA3 is an Endogenous TGF-β Receptor Antagonist that Attenuates Cardiac Fibroblast Activation and Fibrotic Remodeling.

This preclinical study investigated SerpinA3 as an endogenous TGF-β receptor antagonist in cardiac fibroblast activation and fibrotic remodeling using a transverse aortic constriction (TAC) mouse model. SerpinA3K expression was reduced in failing mouse hearts and circulation, and pharmacologic supplementation or genetic augmentation of SerpinA3 markedly attenuated pressure-overload–induced cardiac dysfunction and fibrosis. The results position SerpinA3 as a mechanistically grounded antifibrotic candidate that could complement limited current heart failure therapies.

Wang H, Cui J, Huang C et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials.

This pooled participant-level analysis studied whether time spent within blood pressure (BP) range predicts cardiovascular outcomes in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF). Using data pooled from TOPCAT (Americas), PARAGON-HF, DELIVER, and FINEARTS-HF, the analysis evaluated associations between systolic BP control and subsequent outcomes across trials of spironolactone, sacubitril/valsartan, dapagliflozin, and finerenone versus control. The results aim to refine BP management targets in HFmrEF/HFpEF, where evidence for specific systolic targets has been limited.

Lu H, Claggett BL, Ostrominski JW et al. · European journal of heart failure · (2026) · View on PubMed ↗

---

Cardiovascular Imaging & Diagnostics (Amyloid/Other)

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

This prospective multicenter single-group clinical trial evaluated 124I-evuzamitide PET/CT for diagnosing cardiac amyloidosis across amyloid types in a study of participants enrolled at 18 US centers. The trial assessed the sensitivity and specificity of 124I-evuzamitide PET/CT for detecting cardiac amyloidosis, aiming to overcome limitations of current imaging that primarily targets transthyretin amyloid. If validated, this imaging approach could provide a broadly applicable, noninvasive diagnostic tool for cardiac amyloidosis beyond transthyretin disease.

Dorbala S, Maurer MS, Cuddy SAM et al. · JAMA · (2026) · View on PubMed ↗

---

Cardiovascular Pharmacology & Drug Trials

Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

This updated systematic review evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for weight loss among adults without diabetes using randomized controlled trials of ≥16 weeks. Across 38 RCTs (n=25,816), the review synthesized evidence including 14 additional trials (n=11,000) to update comparative outcomes and adverse-event profiles. Clinically, it informs evidence-based selection and risk–benefit assessment of GLP-1–based anti-obesity therapies in non-diabetic adults.

Moiz A, Filion KB, Samuels AE et al. · Annals of internal medicine · (2026) · View on PubMed ↗

Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.

This reconstructed aggregate-data Bayesian longitudinal meta-analysis estimated weight-regain trajectories after discontinuation of semaglutide or tirzepatide and explored predictors of faster regain using published timepoint-level aggregate data. The key finding was characterization of post-cessation regain dynamics (including time to 50% regain and time to return to baseline weight) and identification of factors associated with faster regain. Scientifically and clinically, it helps quantify expected rebound after stopping these GLP-1/GIP-based therapies and supports counseling and planning for long-term weight management.

Kow CS, Thiruchelvam K, Ramachandram DS et al. · Endocrinology, diabetes & metabolism · (2026) · View on PubMed ↗

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.

This meta-analysis synthesized outcomes from randomized, placebo-controlled phase 3 trials of transthyretin (TTR) gene-silencing therapies in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), with attention to baseline use of TTR stabilizers. Across trials, gene-silencing therapy reduced clinical outcomes in ATTR-CM and the overall effect was assessed for consistency by whether patients were receiving TTR stabilizers. Clinically, the pooled evidence supports the effectiveness of hepatic TTR gene-silencing approaches and helps clarify how background TTR stabilizer use may modify observed benefits.

Gillmore JD, Hamatani Y, Fontana M et al. · JAMA · (2026) · View on PubMed ↗

---

Immunology, Inflammation & Cytokine-ROS Signaling

CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression.

This study investigated how CD9+ germinal center B (GC-B) cells regulate germinal center (GC) regression in adenoid hypertrophy (AH) using single-cell RNA sequencing (scRNA-seq), flow cytometry, and mass cytometry (CyToF). It identified a FOXP1-regulated CD9+ GC-B subset across GC-B development that promotes GC-B cell differentiation toward apoptosis pathways, contributing to GC termination. These findings suggest a CD9–FOXP1 axis as a mechanistic lever for controlling pathological GC persistence in AH and potentially other GC-driven diseases.

Liao W, Song L, Xu M et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

SIRT1 Silences L1 Retrotransposons by Stabilizing Heterochromatin-Modifying Complexes.

This study examined how the sirtuin deacetylase SIRT1 regulates LINE-1 (L1) retrotransposition during cellular senescence, focusing on L1 activity and heterochromatin-modifying complexes. SIRT1 significantly suppressed L1 retrotransposition by stabilizing heterochromatin-modifying complexes, thereby silencing L1 elements and limiting the senescence-associated IFN-I response. These findings link SIRT1-mediated epigenetic control to transposable-element suppression, suggesting a mechanistic route by which SIRT1 may influence aging and age-related inflammatory disease.

Wang X, Li T, Tang H et al. · Aging cell · (2026) · View on PubMed ↗ · Free PDF ↗

Cytokine-associated ROS and Ca2+ dysregulation in severe inflammatory cardiomyopathy.

This study investigated cytokine-associated mechanisms of reactive oxygen species (ROS) generation and Ca2+ dysregulation in severe inflammatory cardiomyopathy (iCMP) using cytokine profiling in patients with biopsy-proven iCMP (n=63) and validation in a national cohort (n=425), followed by induced human cardiomyocyte experiments. It identified key cytokines enriched in severe iCMP and showed that these cytokines promote cardiomyocyte injury by driving ROS production and disrupting calcium homeostasis. Mechanistically, the work highlights cytokine–ROS–Ca2+ signaling as a potential therapeutic target in severe iCMP.

Suwalski P, Golpour A, Weiner J et al. · Cardiovascular research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Infectious Disease & Vaccination/Antivirals

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

In the RECOVER-VITAL phase 2 randomized, double-blind, placebo-controlled trial, adults with long COVID symptoms lasting ≥12 weeks across cognitive, autonomic, or exercise phenotypes were treated at 69 US sites with the SARS-CoV-2 antiviral nirmatrelvir-ritonavir versus placebo. The study tested whether nirmatrelvir-ritonavir improves long COVID symptoms by targeting a viral persistence hypothesis. If effective, this would support an antiviral strategy for persistent post-acute sequelae of SARS-CoV-2 infection in a phenotype-defined adult population.

Baden LR, Shah NS, Liu STH et al. · The Lancet. Infectious diseases · (2026) · View on PubMed ↗

Refractory Azole-Resistant Candida albicans Renal and Perirenal Abscess Requiring Nephrectomy.

This case report studied a man in his 50s with refractory azole-resistant Candida albicans renal and perirenal abscess requiring nephrectomy after failure of fluconazole therapy. The key finding was that acquired azole resistance occurred without ERG11 amino-acid substitutions, while a Rhodamine 6G efflux assay showed a 4.5- to 6.6-fold increase in efflux activity, implicating efflux pump-mediated resistance. Clinically, it emphasizes that azole failure in C. albicans may be driven by efflux mechanisms even when ERG11 is unchanged, affecting diagnostic and treatment decisions.

Mori N, Matsumoto K, Shoji R et al. · Medical mycology journal · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurology: Neurodegeneration, Pain, and Biomarkers

Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society.

This AAN/American Headache Society practice guideline report summarized evidence-based recommendations for pharmacologic migraine prevention in adults based on a systematic review of studies published through June 6, 2024. The key finding was the guideline’s updated, structured recommendations integrating evidence synthesis, care principles, and clinical inferences for selecting preventive medications. Clinically, it provides actionable decision support for clinicians choosing preventive pharmacotherapy for episodic or chronic migraine in adult patients.

Potrebic S, Tanveer S, Becker WJ et al. · Neurology · (2026) · View on PubMed ↗

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

This Neurology systematic review evaluated randomized controlled trials of pharmacologic preventive treatments for adults with episodic or chronic migraine to inform updated AAN/American Headache Society practice guidelines. The key finding was an evidence-based synthesis of trial outcomes across preventive drug classes, using searches of MEDLINE, Embase, and ClinicalTrials.gov through June 6, 2024 with duplicate screening and risk-of-bias assessment. Its significance is to strengthen the evidentiary foundation for guideline recommendations on migraine prevention in adult populations.

Pringsheim T, Smith DB, Tanveer S et al. · Neurology · (2026) · View on PubMed ↗

Military Service and Survival Among Persons With ALS in the U.S. National ALS Registry, 2011-2023.

This registry-based cohort study evaluated whether military service is associated with survival after amyotrophic lateral sclerosis (ALS) diagnosis among U.S. National ALS Registry participants (2011–2023). Using National Death Index linkage and Cox proportional hazards models, it compared survival between veterans and nonveterans. The results help determine whether military service is a prognostic factor in ALS, which could refine risk stratification and inform etiologic hypotheses.

Horton DK, Raymond J, Larson T et al. · Muscle & nerve · (2026) · View on PubMed ↗ · Free PDF ↗

Antidepressant effects of facial botulinum toxin a injections: Insights from randomized controlled trials.

This systematic review and meta-analysis evaluated whether facial injections of botulinum toxin A (BoNT/A) reduce depressive symptoms compared with placebo and the active antidepressant sertraline in randomized controlled trials. Across eight RCTs (n=636), facial BoNT/A significantly reduced depressive symptoms versus control (SMD −0.81, 95% CI −1.23 to −0.38, p<0.001). The findings suggest a potential non-oral, localized antidepressant-like intervention that could complement existing therapies with a faster or different onset profile and a distinct safety consideration.

Gao Z, Chen X, Yu X et al. · Journal of affective disorders · (2026) · View on PubMed ↗

A single-cell meta-analysis evidences transposable element dysregulation in sex-based differences in Parkinson’s disease.

This study performed an integrative single-nucleus RNA-seq meta-analysis across four substantia nigra datasets (66 patients) to characterize transposable element (TE) dysregulation in Parkinson’s disease and its sex-specific effects. It found widespread TE activation across major brain cell types, with neuron-specific upregulation of LINE-1 (L1s) and oligodendrocyte-specific upregulation of human endogenous retroviruses (HERVs), with sex-stratified differences reported. These results implicate specific TE families (L1s, HERVs) in PD pathobiology and motivate sex-aware mechanistic and biomarker studies.

Gordillo-González F, Galiana-Roselló C, Grillo-Risco R et al. · Neurobiology of disease · (2026) · View on PubMed ↗ · Free PDF ↗

Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathway.

This mouse study tested whether intrathecal semaglutide attenuates burn injury-induced pain (BIP) via spinal glucagon-like peptide-1 receptor (GLP-1R) signaling coupled to an enkephalin/δ-opioid receptor pathway. Using a second-degree burn model, the authors assessed nociception and spinal GLP-1R/glial responses with immunoblotting, immunofluorescence, and RNAscope in situ hybridization, then showed semaglutide’s antinociceptive effects were sensitive to pharmacologic GLP-1R antagonism and involved endogenous enkephalin/δ-opioid receptor signaling. The work supports GLP-1R-targeted spinal therapy as a mechanistically grounded analgesic strategy for burn pain.

He Y, Gao J, Liu Y et al. · Neuropharmacology · (2026) · View on PubMed ↗

[Modern treatment of androgenetic alopecia].

This narrative guideline-focused study reviewed modern treatment approaches for androgenetic alopecia by comparing international guidelines and expert consensus statements published between 2015 and 2025. It summarized the applicability of conventional therapies (e.g., topical and systemic options) and how recommendations align across documents. The synthesis is clinically significant for standardizing evidence-based management of a common, chronic hair-loss condition with substantial psychosocial impact.

Rózsa P, Kemény L, Gyulai R · Orvosi hetilap · (2026) · View on PubMed ↗

Modulating the Gut-Microbiota-Brain Axis in Alzheimer’s Disease: Therapeutic Potential of Nutritional and Metabolic Factors.

This review studied therapeutic potential of nutritional and metabolic factors to modulate the gut-microbiota–brain axis in Alzheimer’s disease (AD), integrating preclinical evidence, clinical trial outcomes, mechanistic studies, and Mendelian randomization. It found that dietary interventions and metabolic/nutritional strategies can influence gut microbial composition and downstream neuroinflammatory and neurodegenerative pathways, with varying levels of clinical support. The review supports further development and more rigorous testing of nutrition-based, microbiome-targeted interventions as adjunctive AD therapies.

Xu B, Li X, Dong S et al. · CNS neuroscience & therapeutics · (2026) · View on PubMed ↗ · Free PDF ↗

---

Neurodevelopment & Brain Circuitry

Endogenous opioid dynamics in the dorsal striatum sculpt neural activity to promote goal-directed action.

This Cell study investigated how endogenous dynorphin release from dorsomedial striatum medium spiny neurons (MSNs) and dynorphin–kappa opioid receptor (KOR) signaling regulate neural activity and promote goal-directed action in the dorsal striatum. The key finding was that local, time-locked dynorphin release is necessary and sufficient for goal-directed behavior, linking spatiotemporally precise opioid-neuropeptide dynamics to action selection. Scientifically, it clarifies a causal mechanism for endogenous opioid control of behavior and provides a targetable circuit-level pathway via KOR signaling.

Gowrishankar R, Hjort MM, Elerding AJ et al. · Cell · (2026) · View on PubMed ↗

Predicting cellular responses to perturbation across diverse contexts with State.

This Cell study introduced “State,” a machine-learning model trained on single-cell gene expression data to predict transcriptomic responses to perturbations while accounting for cellular heterogeneity across and within experiments. State improved discrimination of perturbation effects by >30% on large datasets and more accurately identified differentially expressed genes across genetic, signaling, and chemical perturbations than baseline approaches. The scientific significance is a more generalizable framework for forecasting cellular responses to perturbations across diverse biological contexts.

Adduri AK, Gautam D, Bevilacqua B et al. · Cell · (2026) · View on PubMed ↗

Interval-Based Aerobic Exercise and Behavioral Intervention for Sleep Disturbances in Children With Autism Spectrum Disorder: A Randomized Controlled Trial.

This randomized controlled trial studied whether interval-based aerobic exercise plus parent behavioral education (IAE-PBE) improves sleep and related outcomes in 28 children with autism spectrum disorder (ASD) and sleep disturbances, compared with parent behavioral education (PBE) alone. Sleep was assessed by actigraphy and attention by age-appropriate Conners’ Continuous Performance Tests, with the trial evaluating short-term effects over a 2-week intervention. If effective, IAE-PBE could provide a practical, nonpharmacologic strategy to reduce ASD-associated sleep disruption and improve daytime attention functioning.

Lu PT, Yang CY, Huang FY et al. · Autism research : official journal of the International Society for Autism Research · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Biology: Metabolism, Epigenetics & Cell Death

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer.

This study examined the role of the m6A reader YTHDC1 in triple-negative breast cancer (TNBC) metabolic adaptation under lethal metabolic stress. YTHDC1 was specifically overexpressed in TNBC and orchestrated m6A-dependent rewiring by stabilizing GLUT3 mRNA to sustain glucose uptake/NADPH production while reducing ATF4 mRNA stability to suppress SLC7A11-mediated cystine uptake. Targeting the YTHDC1–m6A–GLUT3/ATF4 axis may represent a therapeutic approach to overcome metabolic stress in TNBC.

Lai ZH, Wang Y, Li NN et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Charting Endocrine Progenitors Across Species and Organs.

This cross-species, cross-organ study mapped endocrine progenitors (EPs) across mouse and human pancreas and intestine using single-cell transcriptomics and epigenomics, complemented by mouse bulk proteomics. It uncovered conserved and distinct gene regulatory networks and cell–cell communication patterns that govern endocrine lineage formation during endogenogenesis across organs and systems. The resulting regulatory maps provide a framework for understanding how endocrine development is altered in obesity and diabetes and for identifying lineage-specific therapeutic targets.

Jing C, Sterr M, Caliskan ÖS et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Deubiquitination of Vangl by USP6 and USP32 Regulates Planar Cell Polarity Signaling.

This study investigated how deubiquitination regulates planar cell polarity (PCP) signaling by controlling Vangl1/Vangl2 protein stability. It identified USP6 and USP32 as deubiquitinases that stabilize Vangl proteins via linkage-specific mechanisms—USP6 removing K33-linked and multi-monoubiquitin signals from plasma membrane-associated Vangl2 and USP32 acting through a distinct ubiquitin linkage preference. These findings clarify how Vangl turnover tunes PCP signaling, informing mechanisms of developmental patterning defects and PCP-driven malignancy.

Zha F, Feng D, Xue Z et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

AARS1-Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer.

This study investigated how alanyl tRNA synthetase 1 (AARS1) drives aggressive and recurrent bladder cancer by rewiring glycolysis through H3K27 lactylation. AARS1 was upregulated in bladder cancer, enriched in muscle-invasive and recurrent tumors, and promoted proliferation, EMT, invasion, apoptosis resistance, tumor growth, and lung colonization while enhancing PI3K pathway output, glycolytic flux, and lactate production. These findings position the AARS1–H3K27 lactylation–glycolysis axis as a mechanistic driver and potential therapeutic target for recurrence-prone bladder cancer.

Yuan Q, Song T, He Y et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

IFI27 and BAX are Essential for GSDME-Mediated Myeloma Cell Pyroptosis.

This mechanistic study examined how IFI27 and BAX regulate GSDME-mediated pyroptosis in multiple myeloma (MM) cells. It found that the interferon-alpha–inducible protein IFI27 is upregulated in pyroptotic MM cells and that IFI27 overexpression triggers pyroptosis in MM cell lines and newly diagnosed MM cells in a GSDME-dependent manner, requiring IFI27-driven mitochondrial disruption and the pro-apoptotic factor BAX. The work identifies IFI27 and BAX as essential components of a potential pyroptosis-based therapeutic pathway for MM.

Cui Y, Sun Y, Liu Z et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

WTAP Transcriptional Suppression by KLF9 Drives Osteoclastogenesis via M6A-Mediated Regulation of CSF1R Signaling in Estrogen-Deficient Osteoporosis.

This study investigated how WTAP transcriptional suppression by KLF9 drives osteoclastogenesis in estrogen-deficient osteoporosis via m6A-dependent regulation of CSF1R signaling. In mice, myeloid-specific Wtap knockout worsened osteoclast formation and bone loss, and mechanistically WTAP promoted m6A deposition on Csflr mRNA to enable YTHDF2-mediated degradation and downregulate CSF1R expression, while KLF9 induction suppressed WTAP. The findings link KLF9–WTAP–m6A–YTHDF2 control of CSF1R to osteoclast activation, suggesting epitranscriptomic targets for osteoporosis therapy.

Shen C, Liu X, Ge G et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

NAD+ precursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria.

This preclinical study tested whether nicotinamide riboside (NR), an NAD+ precursor, prevents cardiomyopathy in “mutator” mice with mitochondrial progeria while assessing tissue-specific effects on erythropoiesis. NR treatment prevented or reduced cardiomyopathy but disrupted erythroid maturation, worsening anemia, and in bone marrow it caused reductive stress with altered NADH/NADPH and impaired heme biosynthesis. The results indicate that NAD+ restoration can have beneficial cardiac effects yet harmful hematopoietic consequences, underscoring the need for careful tissue-targeted strategies.

Khan NA, Ahlqvist K, Pradhan S et al. · Cell reports · (2026) · View on PubMed ↗ · Free PDF ↗

---

Cancer Therapies & Translational/Clinical Oncology

Phase 3 Randomized Trial Results of DTX401 AAV Gene Therapy for the Treatment of GSDIa.

This phase 3, double-blind, randomized, placebo-controlled trial evaluated DTX401, an AAV8 vector delivering the human G6PC gene, in patients aged ≥8 years with glycogen storage disease type Ia (GSDIa) due to biallelic pathogenic G6PC variants. The primary efficacy endpoint compared percent change from baseline to week 48 in daily cornstarch intake between DTX401 and placebo groups (with a subsequent crossover after the primary efficacy analysis period). If positive, DTX401 would represent a gene-therapy approach targeting the underlying G6PC deficiency to improve metabolic control in a rare, life-threatening pediatric/adolescent/adult population.

Mitchell JJ, Abdenur JE, de Boer F et al. · Journal of inherited metabolic disease · (2026) · View on PubMed ↗

Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells.

This PNAS open-label, dose-escalation phase Ib clinical trial tested antigen-specific immune tolerance in multiple sclerosis by administering autologous red blood cells coupled to seven immunodominant myelin peptides (pcRBCs). The key findings were that pcRBCs were safe and well tolerated, several clinical/imaging measures remained stable with reduced neurofilament light chain suggesting decreased brain inflammation, and single-cell RNA sequencing showed expansion of antigen-specific T regulatory cells. Scientifically and clinically, it supports a peptide-coupled RBC strategy to induce antigen-specific Tregs as a potential organ-targeted immunotherapy for MS.

Lutterotti A, Ludersdorfer T, Docampo MJ et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗

CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.

This review summarized evidence for CAR-engineered cell therapies beyond cancer, focusing on how CAR platforms are being adapted for autoimmune, inflammatory, and fibrotic diseases. It highlighted early clinical signals for CD19- or BCMA-directed CAR-T cells in refractory autoimmune diseases (including deep B-cell/plasma-cell depletion and sustained remission in selected patients) while noting that fibrosis evidence remains largely preclinical. The review underscores the need for better comparative efficacy, durability, and long-term safety data across CAR targets and disease settings.

Xu PJ, Zhang ZJ, Jin J et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · (2026) · View on PubMed ↗ · Free PDF ↗

Systemic therapy-induced resistance and toxicity in breast cancer: Sensitization and mitigation strategies.

This review examined how standard systemic therapies for breast cancer—including paclitaxel, doxorubicin, tamoxifen, cisplatin, and 5-fluorouracil—drive acquired resistance and organ toxicities, and it evaluated sensitization and mitigation strategies. The key finding is that resistance evolution commonly leads to treatment failure and metastasis while therapeutic efficacy is constrained by toxicity across multiple organs. Scientifically and clinically, it consolidates emerging approaches to overcome resistance and reduce adverse effects to improve outcomes in advanced breast cancer.

Samudrala AS, Nagaraju GP, Malla R · Biochimica et biophysica acta. Reviews on cancer · (2026) · View on PubMed ↗

Biomaterials in Retinal Surgery: Engineering the Future.

This narrative expert review summarized current and emerging biomaterials used in retinal surgery, including vitreous tamponade agents, retinal prostheses, retinal pigment epithelium (RPE) transplant scaffolds, intraocular drug delivery platforms, and gene therapy vectors, with emphasis on oxime-crosslinked hyaluronic acid vitreous substitutes. The key finding is that multiple biomaterial classes are being engineered to address specific retinal clinical needs (support, delivery, and tissue replacement), and that oxime-crosslinked hyaluronic acid is highlighted as a promising vitreous substitute. Scientifically, it frames how biomaterial design and translational evidence (preclinical to FDA-approved/clinical trial contexts) can guide future retinal regenerative and drug-delivery strategies.

Dindar IA, Shoichet MS, Labriola J et al. · American journal of ophthalmology · (2026) · View on PubMed ↗

An Immune-Activated Co-culture Model of Patient-Derived Gastric Cancer Organoids and Peripheral Blood Mononuclear Cells for Personalized Chemotherapy Screening.

This study developed an immune-activated co-culture model using patient-derived gastric cancer organoids and autologous peripheral blood mononuclear cells (PBMCs) to enable personalized chemotherapy screening after immunotherapy. Immune activation was achieved using anti-PD-1-loaded gold nanocages (aPD-1@Au NCs), and the model was designed to preserve immune–tumor interactions while testing subsequent chemotherapy responses. The clinical significance is a step toward more faithful preclinical testing of treatment sequencing in advanced gastric cancer with heterogeneous patient responses.

Yu Y, Chen W, Jia N et al. · Acta biomaterialia · (2026) · View on PubMed ↗

Real-world adherence and healthcare resource utilization following transition to aripiprazole once-every-2-months from oral or once-monthly aripiprazole among patients diagnosed with schizophrenia in the United States.

This retrospective real-world claims study evaluated adherence and healthcare resource utilization in U.S. adults with schizophrenia who transitioned from oral aripiprazole or once-monthly aripiprazole monohydrate to aripiprazole monohydrate 2-month ready-to-use (Ari 2MRTU). Following the transition, adherence improved (PDC and MPR increased) and healthcare resource utilization outcomes were assessed in the 6 months before versus after index. The findings suggest that extending dosing to every 2 months may improve medication-taking behavior and potentially reduce downstream utilization burden in schizophrenia care.

Harrsen K, Yildirim M, Beckham C et al. · Current medical research and opinion · (2026) · View on PubMed ↗ · Free PDF ↗

---

Hematologic Malignancies & Immune Toxicities

Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.

This case report studied immune-related adverse events in a 56-year-old man with stage IV nodular sclerosis classic Hodgkin lymphoma who relapsed after multiple prior therapies and then received pembrolizumab plus gemcitabine/vinorelbine/liposomal doxorubicin (GVD). After achieving a complete metabolic response, he developed marked leukocytosis with profound eosinophilia consistent with hypereosinophilic syndrome and suspected myeloid neoplasia during immune checkpoint inhibitor therapy. The report highlights a rare but clinically important spectrum of hematologic toxicity that can mimic or reveal underlying myeloid disease during PD-1 blockade.

Ibrahim RAE, Ahmed BA, Bahr AR et al. · Leukemia & lymphoma · (2026) · View on PubMed ↗

CD74 in hematological malignancies: from MHC chaperone to therapeutic target.

This review studied CD74 biology in hematological malignancies, focusing on its role as an MHC class II invariant chain and signaling hub across immune cell types and cancer contexts. It found that CD74 is broadly and strongly expressed in acute/chronic leukemias, lymphomas, and multiple myeloma, and that its rapid internalization and limited normal-tissue expression make it a promising therapeutic target. The work supports continued development of CD74-directed therapies (e.g., antibody-based strategies) for a wide range of hematologic cancers.

Zhang S, Xiong S, Cao J et al. · Leukemia & lymphoma · (2026) · View on PubMed ↗

---

Gastroenterology & Hepatology (including GI eosinophilic disease)

Endoscopic Ultrasound-guided Gastroenterostomy: An International Consensus on Current and Expanding Indications, Techniques, Periprocedural Care and Institutional Requirements.

This international consensus used a structured modified Delphi process with 66 expert panelists to synthesize evidence and expert agreement on endoscopic ultrasound-guided gastroenterostomy (EUS-GE) and related EUS-guided anastomoses for gastric outlet obstruction and other complex gastrointestinal indications. The key output was standardized recommendations covering current and expanding indications, technical/periprocedural care, and institutional requirements despite heterogeneity in practice. Clinically, the consensus aims to improve safety, consistency, and implementation of EUS-GE across centers performing these procedures.

Vanella G, Neesse A, Binda C et al. · Endoscopy · (2026) · View on PubMed ↗

Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

This randomized, double-blind, placebo-controlled multicenter trial studied oral submicron-powdered curcumin (Theracurmin® 180 mg twice daily) versus placebo for 2 years in patients with previously endoscopically resected colorectal neoplasia. The key finding is that curcumin suppressed the growth of recurrent colorectal adenoma after endoscopic resection. Clinically, this supports curcumin as a potential noninvasive chemopreventive option to reduce adenoma recurrence risk following polypectomy.

Takayama T, Okamoto K, Ishikawa H et al. · The American journal of gastroenterology · (2026) · View on PubMed ↗

Cendakimab for Eosinophilic Gastritis and Duodenitis in Japanese Adults and Adolescents: Results From a Phase 3 Randomized Controlled Trial.

This phase 3 randomized, double-blind, placebo-controlled trial studied cendakimab, an anti–IL-13 monoclonal antibody, in 48 Japanese adults and adolescents with eosinophilic gastritis and/or eosinophilic duodenitis. The key finding was that at week 16 cendakimab significantly reduced mean peak gastrointestinal eosinophil counts versus placebo (least squares mean difference −223.2 eosinophils/high-power field; P=0.003), with histologic improvements maintained at week 48 and a favorable safety profile. Scientifically and clinically, it provides evidence for IL-13 blockade as an effective targeted therapy for this rare eosinophilic GI disease.

Kinoshita Y, Oka S, Matsushima K et al. · The American journal of gastroenterology · (2026) · View on PubMed ↗

Risk Assessment in MASLD and MetALD: Current Approaches and Future Directions.

This article reviewed current and emerging noninvasive risk-assessment strategies for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-related liver disease (MetALD), focusing on fibrosis staging in clinical populations. It found that fibrosis stage is the dominant predictor of liver-related complications and that stepwise triage using serum scores (e.g., FIB-4) followed by vibration-controlled transient elastography (VCTE) or liver-specific blood tests (ELF, PRO-C3) improves risk stratification, with magnetic resonance elastography (MRE) offering higher accuracy than ultrasound-based elastography. Clinically, the review supports using serum-first algorithms with elastography or fibrosis biomarkers to better identify patients needing referral and closer management.

Lin H, Wang H, Yang K et al. · Clinical and molecular hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

Molecular Mechanisms and Regulatory Networks of Salt Stress Tolerance in Plant.

This review article synthesized molecular mechanisms and regulatory networks underlying plant salt stress tolerance, focusing on how plants sense salinity and coordinate downstream responses. It highlights key sensory/signaling modules such as calcium signaling and receptor-like kinases (including FERONIA), as well as ion homeostasis, osmotic adjustment, hormone signaling, transcript regulation, and protein modification. The scientific significance is that mapping these pathways (e.g., OSCA/MOCA and annexin-related components) can inform strategies to engineer or breed salt-tolerant crops.

Usman M, Wang L, Xiaojuan A et al. · Plant science : an international journal of experimental plant biology · (2026) · View on PubMed ↗

Clinical and Metabolomic Panel for Noninvasive Screening of Biopsy-Confirmed MASH in Children and Adolescents.

This study aimed to develop and validate a clinical plus metabolomics panel to noninvasively screen for biopsy-confirmed pediatric metabolic dysfunction-associated steatohepatitis (MASH) in children and adolescents. Using fasting serum from NASH CRN participants and healthy controls, it performed untargeted LC-MS metabolomics and combined metabolite signatures with clinical variables (anthropometrics, lipids, liver enzymes, insulin resistance markers), with MASH defined by biopsy in NASH CRN participants and hepatic steatosis in healthy participants assessed by MRI-PDFF. The clinical significance is a potential noninvasive screening tool to identify children with MASH who would otherwise require invasive biopsy.

Huneault HE, Sudhakar SG, Gent AE et al. · JHEP reports : innovation in hepatology · (2026) · View on PubMed ↗ · Free PDF ↗

---

---

Generated automatically on September 01, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.